Activity of erlotinib when dosed below the maximum tolerated dose forEGFR-mutant lung cancer: Implications for targeted therapy development-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Activity of erlotinib when dosed below the maximum tolerated dose forEGFR-mutant lung cancer: Implications for targeted therapy development

Published:2016-08-15 Issue:22 Volume:122 Page:3456-3463
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Lampson Benjamin L.¹,Nishino Mizuki²,Dahlberg Suzanne E.³⁴,Paul Danie³,Santos Abigail A.⁵,Jänne Pasi A.¹⁵,Oxnard Geoffrey R.¹⁵

Affiliation:

1. Department of Medical Oncology; Dana-Farber Cancer Institute; Boston Massachusetts

2. Department of Radiology; Dana-Farber Cancer Institute and Brigham and Women's Hospital; Boston Massachusetts

3. Department of Biostatistics and Computational Biology; Dana-Farber Cancer Institute; Boston Massachusetts

4. Department of Biostatistics; Harvard T. H. Chan School of Public Health; Boston Massachusetts

5. Lowe Center for Thoracic Oncology; Dana-Farber Cancer Institute; Boston Massachusetts

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference28 articles.

1. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol.,2011

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012

3. Crizotinib in ROS1-rearranged non-small-cell lung cancer;Shaw;N Engl J Med.,2014

4. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med.,2013

5. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study;McArthur;Lancet Oncol.,2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology;Clinical Pharmacokinetics;2023-08-16

2. Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma;Therapeutic Advances in Medical Oncology;2023-01

3. Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients;Cancer Chemotherapy and Pharmacology;2022-07-12

4. Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer;Drugs;2021-12-11

5. Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature;Expert Opinion on Drug Metabolism & Toxicology;2021-07-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3